Lancet:降低心血管风险还是增加风险?防癌还是致癌?——体重决定了阿司匹林对血管事件和癌症风险的影响

2018-07-13 zhangfan MedSci原创

研究发现,阿司匹林对心血管及肿瘤的预防效果与身体大小密切相关仅对于体重低于70kg人群,服用75-100mg小剂量阿司匹林可降低心血管事件风险,对于超过80%的男性及超过50%女性人群,服用小剂量阿司匹林是无效的;反之,高剂量阿司匹林仅对70kg以上人群有益,阿司匹林对肿瘤的预防效果也与密切体重相关。因此研究人员认为需要探究更为合理有效,甚至是个体化的阿司匹林给药方法

统计发现,长期服用阿司匹林用于预防血管事件的效果很难达到预期,这可能是由于大体型的患者服用剂量过低或小体型患者服用过量的导致的。

近日研究人员依据体重(每10Kg为一组)和身高(每10cm为一组),对低剂量 (≤100 mg)或高剂量(300-325 mg 或≥500 mg)阿司匹林的心血管疾病预防效果进行了考察,同时研究考察了不同体重及身高人群服用阿司匹林对20年后结肠癌发病风险的影响。

总计10个研究,117279名参与者纳入本次研究,参与者体重范围60-81.2Kg。研究发现,服用75-100mg阿司匹林降低心血管事件的效果随体重的增加而降低,体重50-69kg人群受到的保护最大(心血管死亡HR=0.75),但对于体重70kg以上人群保护作用显著降低(心血管死亡HR=0.95);更有甚者,对于体重70kg以上人群,服用小剂量阿司匹林增加首次心血管事件风险(OR=1.33);服用超过325 mg阿司匹林可降低大体重人群的心血管风险,上述结果不受性别、糖尿病以及二级预防的影响。阿司匹林预防结直肠癌的长期风险也与体重有关,过量服用阿司匹林增加了低体重人群猝死的风险,对于体重低于50kg且服用75-100mg阿司匹林人群其全因死亡风险增加(HR=1.52)。对于70岁以上老年人群,服用阿司匹林增加3年肿瘤风险(HR=1.20),特别对于体重低于70kg(HR=1.31)或老年女性人群(HR=1.44),服用阿司匹林导致的肿瘤风险更高。

研究发现,阿司匹林对心血管及肿瘤的预防效果与身体大小密切相关仅对于体重低于70kg人群,服用75-100mg小剂量阿司匹林可降低心血管事件风险,对于超过80%的男性及超过50%女性人群,服用小剂量阿司匹林是无效的;反之,高剂量阿司匹林仅对70kg以上人群有益,阿司匹林对肿瘤的预防效果也与密切体重相关。因此研究人员认为需要探究更为合理有效,甚至是个体化的阿司匹林给药方法。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643547, encodeId=3549164354ecd, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Nov 21 05:52:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829714, encodeId=6d351829e143f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jun 01 08:52:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082465, encodeId=19172082465d6, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Sep 07 15:52:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818659, encodeId=cce0181865902, content=<a href='/topic/show?id=841398124b3' target=_blank style='color:#2F92EE;'>#降低心血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98124, encryptionId=841398124b3, topicName=降低心血管风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Mon Jun 10 19:52:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370949, encodeId=044913e0949e9, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Jul 15 03:52:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488046, encodeId=6e0b148804643, content=<a href='/topic/show?id=5c699e46010' target=_blank style='color:#2F92EE;'>#防癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97460, encryptionId=5c699e46010, topicName=防癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6d78400961, createdName=jeanqiuqiu, createdTime=Sun Jul 15 03:52:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331431, encodeId=768233143131, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jul 14 00:16:37 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331314, encodeId=54f533131411, content=非常不错的!学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Fri Jul 13 14:14:53 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1643547, encodeId=3549164354ecd, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Nov 21 05:52:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829714, encodeId=6d351829e143f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jun 01 08:52:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082465, encodeId=19172082465d6, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Sep 07 15:52:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818659, encodeId=cce0181865902, content=<a href='/topic/show?id=841398124b3' target=_blank style='color:#2F92EE;'>#降低心血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98124, encryptionId=841398124b3, topicName=降低心血管风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Mon Jun 10 19:52:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370949, encodeId=044913e0949e9, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Jul 15 03:52:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488046, encodeId=6e0b148804643, content=<a href='/topic/show?id=5c699e46010' target=_blank style='color:#2F92EE;'>#防癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97460, encryptionId=5c699e46010, topicName=防癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6d78400961, createdName=jeanqiuqiu, createdTime=Sun Jul 15 03:52:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331431, encodeId=768233143131, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jul 14 00:16:37 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331314, encodeId=54f533131411, content=非常不错的!学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Fri Jul 13 14:14:53 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2019-06-01 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1643547, encodeId=3549164354ecd, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Nov 21 05:52:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829714, encodeId=6d351829e143f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jun 01 08:52:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082465, encodeId=19172082465d6, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Sep 07 15:52:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818659, encodeId=cce0181865902, content=<a href='/topic/show?id=841398124b3' target=_blank style='color:#2F92EE;'>#降低心血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98124, encryptionId=841398124b3, topicName=降低心血管风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Mon Jun 10 19:52:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370949, encodeId=044913e0949e9, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Jul 15 03:52:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488046, encodeId=6e0b148804643, content=<a href='/topic/show?id=5c699e46010' target=_blank style='color:#2F92EE;'>#防癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97460, encryptionId=5c699e46010, topicName=防癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6d78400961, createdName=jeanqiuqiu, createdTime=Sun Jul 15 03:52:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331431, encodeId=768233143131, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jul 14 00:16:37 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331314, encodeId=54f533131411, content=非常不错的!学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Fri Jul 13 14:14:53 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1643547, encodeId=3549164354ecd, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Nov 21 05:52:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829714, encodeId=6d351829e143f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jun 01 08:52:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082465, encodeId=19172082465d6, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Sep 07 15:52:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818659, encodeId=cce0181865902, content=<a href='/topic/show?id=841398124b3' target=_blank style='color:#2F92EE;'>#降低心血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98124, encryptionId=841398124b3, topicName=降低心血管风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Mon Jun 10 19:52:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370949, encodeId=044913e0949e9, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Jul 15 03:52:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488046, encodeId=6e0b148804643, content=<a href='/topic/show?id=5c699e46010' target=_blank style='color:#2F92EE;'>#防癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97460, encryptionId=5c699e46010, topicName=防癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6d78400961, createdName=jeanqiuqiu, createdTime=Sun Jul 15 03:52:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331431, encodeId=768233143131, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jul 14 00:16:37 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331314, encodeId=54f533131411, content=非常不错的!学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Fri Jul 13 14:14:53 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1643547, encodeId=3549164354ecd, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Nov 21 05:52:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829714, encodeId=6d351829e143f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jun 01 08:52:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082465, encodeId=19172082465d6, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Sep 07 15:52:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818659, encodeId=cce0181865902, content=<a href='/topic/show?id=841398124b3' target=_blank style='color:#2F92EE;'>#降低心血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98124, encryptionId=841398124b3, topicName=降低心血管风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Mon Jun 10 19:52:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370949, encodeId=044913e0949e9, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Jul 15 03:52:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488046, encodeId=6e0b148804643, content=<a href='/topic/show?id=5c699e46010' target=_blank style='color:#2F92EE;'>#防癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97460, encryptionId=5c699e46010, topicName=防癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6d78400961, createdName=jeanqiuqiu, createdTime=Sun Jul 15 03:52:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331431, encodeId=768233143131, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jul 14 00:16:37 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331314, encodeId=54f533131411, content=非常不错的!学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Fri Jul 13 14:14:53 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-07-15 jambiya
  6. [GetPortalCommentsPageByObjectIdResponse(id=1643547, encodeId=3549164354ecd, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Nov 21 05:52:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829714, encodeId=6d351829e143f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jun 01 08:52:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082465, encodeId=19172082465d6, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Sep 07 15:52:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818659, encodeId=cce0181865902, content=<a href='/topic/show?id=841398124b3' target=_blank style='color:#2F92EE;'>#降低心血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98124, encryptionId=841398124b3, topicName=降低心血管风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Mon Jun 10 19:52:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370949, encodeId=044913e0949e9, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Jul 15 03:52:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488046, encodeId=6e0b148804643, content=<a href='/topic/show?id=5c699e46010' target=_blank style='color:#2F92EE;'>#防癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97460, encryptionId=5c699e46010, topicName=防癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6d78400961, createdName=jeanqiuqiu, createdTime=Sun Jul 15 03:52:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331431, encodeId=768233143131, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jul 14 00:16:37 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331314, encodeId=54f533131411, content=非常不错的!学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Fri Jul 13 14:14:53 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-07-15 jeanqiuqiu
  7. [GetPortalCommentsPageByObjectIdResponse(id=1643547, encodeId=3549164354ecd, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Nov 21 05:52:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829714, encodeId=6d351829e143f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jun 01 08:52:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082465, encodeId=19172082465d6, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Sep 07 15:52:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818659, encodeId=cce0181865902, content=<a href='/topic/show?id=841398124b3' target=_blank style='color:#2F92EE;'>#降低心血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98124, encryptionId=841398124b3, topicName=降低心血管风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Mon Jun 10 19:52:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370949, encodeId=044913e0949e9, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Jul 15 03:52:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488046, encodeId=6e0b148804643, content=<a href='/topic/show?id=5c699e46010' target=_blank style='color:#2F92EE;'>#防癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97460, encryptionId=5c699e46010, topicName=防癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6d78400961, createdName=jeanqiuqiu, createdTime=Sun Jul 15 03:52:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331431, encodeId=768233143131, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jul 14 00:16:37 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331314, encodeId=54f533131411, content=非常不错的!学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Fri Jul 13 14:14:53 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-07-14 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1643547, encodeId=3549164354ecd, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Nov 21 05:52:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829714, encodeId=6d351829e143f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jun 01 08:52:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082465, encodeId=19172082465d6, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Sep 07 15:52:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818659, encodeId=cce0181865902, content=<a href='/topic/show?id=841398124b3' target=_blank style='color:#2F92EE;'>#降低心血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98124, encryptionId=841398124b3, topicName=降低心血管风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Mon Jun 10 19:52:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370949, encodeId=044913e0949e9, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Jul 15 03:52:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488046, encodeId=6e0b148804643, content=<a href='/topic/show?id=5c699e46010' target=_blank style='color:#2F92EE;'>#防癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97460, encryptionId=5c699e46010, topicName=防癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6d78400961, createdName=jeanqiuqiu, createdTime=Sun Jul 15 03:52:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331431, encodeId=768233143131, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jul 14 00:16:37 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331314, encodeId=54f533131411, content=非常不错的!学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Fri Jul 13 14:14:53 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-07-13 13718711b3m

    非常不错的!学习了.获益匪浅.感谢分享

    0

相关资讯

Hypertension:1期高血压的准妈妈服用阿司匹林可否降低先兆子痫风险?

2018年7月,发表于《Hypertension》上的一项研究,考察了高风险队列中,阿司匹林对与1期高血压相关的不良妊娠结局的影响。

Am J Obstet Gynecol:先兆子痫高风险孕妇 阿司匹林能减少小宝宝的NICU时间?

先兆子痫是一种严重的妊娠并发症,谈之色变,对母亲和孩子短期和长期均有不良影响。通过综合考察孕妇人口统计学特征和病史与生物标志物测量指标,在妊娠11~13周筛查先兆子痫,可识别出约75%妊娠<37周发生早产先兆子痫的女性和90%妊娠<32周发生早发先兆子痫的女性,筛查阳性率为10%。

JAMA:轻微神经功能受损的急性缺血性脑卒中患者不易接受阿替普酶治疗

研究认为对于轻度非致残性急性缺血性脑卒中患者,相比于阿司匹林阿替普酶治疗不能提高患者90天功能预后

风湿患者用小剂量阿司匹林时,还能加用其他非甾体抗炎药吗?

应用阿司匹林患者应尽量避免加用其他NSAIDs,但对因并发了关节炎类疾病而需应用其他NSAIDs的患者,该如何处理?

Gastroenterology:米索前列醇可治疗因阿司匹林导致的小肠出血

研究认为,对于因阿司匹林持续治疗导致小肠出血的患者,米索前列醇可在不停药的情况下促进小肠溃疡面愈合

Best of ASCO 2018 China:胃肠肿瘤专场精彩回顾(1)——AspECT 阿司匹林与埃索美拉唑预防Barrett’s食管化生的III期对照研

2018年7月5-8日,中国临床肿瘤学会(CSCO)联合美国临床肿瘤学会(ASCO)在合肥成功举办了“临床肿瘤学新进展学术研讨会——Best of ASCO(BOA)2018 China”。2天的时间,解读了39项研究摘要,12场专家点评,4个研究进展述评。来自全国各地2000余名专家学者,汇聚合肥,回顾研究进展,共同探讨和交流这些研究对我国临床实践的影响。以下分享胃肠肿瘤专场精彩内容。